METABORA GAMES Integrates BORA Ecosystem with Kaia CL Protocol
SEOUL, South Korea, Aug. 7, 2025 /PRNewswire/ — METABORA GAMES (CEO Choi Se-hoon), a leading blockchain game developer, announced today that it has completed the integration of the 'Consensus Liquidity (CL) Protocol' of the blockchain platform Kaia into the BORA ecosystem.
The 'CL' is an innovative infrastructure protocol based on the Kaia chain that enables simultaneous participation in validator staking and liquidity provision.
By integrating Kaia's CL technology into the BORA ecosystem, METABORA GAMES will begin full-scale connectivity with external chains through the establishment of a joint liquidity pool, the introduction of a 'gas abstraction' model (which enables transaction fees to be paid on behalf of users), and the implementation of a fee-burning mechanism.
With the completion of the CL integration, METABORA GAMES and the Kaia Foundation established a joint liquidity provision plan and provided approximately $2 million in liquidity as of August 5. The partners plan to further boost the BORA ecosystem and enhance the token's value through additional phased liquidity injections.
Additionally, a burn mechanism will be applied to the fee revenue generated from the joint liquidity pool. A certain portion of BORA-denominated profits will be burned, reinforcing the ecosystem's deflationary tokenomics. The burn rate and frequency will be adjusted flexibly in accordance with market conditions and revenue scale.
The integration will also introduce a 'gas abstraction' feature, allowing users to pay transaction fees on the Kaia mainnet using BORA tokens. This enables users to cover transaction fees with BORA tokens even if they do not hold any Kaia tokens.
A METABORA GAMES representative stated, 'The integration of the CL Protocol marks the first step for the BORA chain in achieving functional flexibility and scalability by structurally connecting with external public infrastructure. This signifies a transition and expansion from an independent BORA mainnet model to an interactive structure that engages with external ecosystems.' They added, 'Starting with the launch of mini Dapps based on LINE Messenger and onboarding on Kaia, we will further strengthen BORA's tokenomics by expanding external utility and operating an organic burn mechanism that functions seamlessly across multiple chains.'
About METABORA
METABORA is a casual game developer and the service operator of the blockchain platform BORA.
The BORA ecosystem brings together partners across various industries—ranging from tokenomics and content to blockchain technology—driving innovation and collaboration across games, sports, and entertainment.
BORA is a national game/entertainment token with a high liquidity in the market and reinforcing the accessibility of users and services abroad by increasing the listing on global cryptocurrency exchanges and expanding partnership.
Photo – https://mma.prnewswire.com/media/2745884/METABORA_GAMES_Integrates_BORA_Ecosystem_with_Kaia_CL_Protocol.jpg
View original content:https://www.prnewswire.co.uk/news-releases/metabora-games-integrates-bora-ecosystem-with-kaia-cl-protocol-302523928.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
30 minutes ago
- Malaysian Reserve
Kubit Launches 'Ask Kubit': Explainable AI for Customer Journey Analytics
LOS ALTOS, Calif., Aug. 7, 2025 /PRNewswire/ — Kubit, the leading customer journey analytics platform, today announced the launch of Ask Kubit, a conversational AI interface that allows teams to ask questions in plain English and receive instant answers from their own data, no SQL or builder. This new feature is designed to empower product managers, data analysts, and business leaders to access the insights they need faster and more intuitively. Built on the foundation of Kubit Lumos, Ask Kubit introduces explainable AI (xAI) into everyday analytics, further advancing the platform's mission to make insights more accessible, transparent, and self‑service. 'At Kubit, we believe analytics should be as easy as asking a question,' said Alex Li, Founder & CEO of Kubit. 'With Ask Kubit, any product manager, analyst or executive can simply type a question and our Lumos AI engine will interpret their intent and generate a complete report in seconds. By connecting directly to your data warehouse, we deliver answers with full transparency – no code, no bottlenecks and no black‑box logic.' Key Capabilities of Ask Kubit Natural Language Questions: Simply ask a question in everyday language; Ask Kubit translates it into a query and delivers the answer with context and clarity. Smart Suggestions: Users receive AI‑powered follow‑up questions and related queries to deepen their analysis without needing to leave the interface. Source‑of‑Truth Metrics: Answers are generated directly from your data warehouse and governed metrics, ensuring transparency and trust. Integrated with Lumos: Ask Kubit is built on Kubit Lumos, extending its NLP, summarization and AI capabilities into a fully conversational experience. With Kubit Lumos, the guiding principle was to build an AI tool that's genuinely useful, transparent and trustworthy. Kubit reduced hallucinations and harnessed the secure metadata already shared with Kubit to deliver accurate, context‑aware responses, hallmarks of true explainable AI. Ask Kubit is now available to Enterprise customers. By combining AI‑powered discovery with a warehouse‑native architecture, Kubit continues to eliminate data silos, empower self‑service analytics and reduce the time between question and answer, while keeping teams in full control of their data. 'As we bring AI deeper into analytics, transparency matters more than ever,' added Jeremy Benza, VP of Product at Kubit. 'Ask Kubit makes it easy for anyone to explore data by simply asking a question, but the real value lies in how we deliver the answer. Because Ask Kubit runs directly on your cloud data warehouse, there's no hidden layer or black‑box logic, ensuring that every response is grounded in governed, reliable data. That's what makes it explainable AI, not just AI.' To learn more about Ask Kubit, visit the Kubit webpage. About Kubit Kubit is a transparent customer journey analytics platform that connects directly to your data warehouse: no duplication, no silos, no confusion. Everyone works from the same trusted source with full visibility into the SQL behind every report. Kubit unifies insights across every stage of the user journey – without ETL headaches – adapts to any data model, and delivers self-service exploration powered by Lumos AI. By bridging technical and business teams, Kubit accelerates time-to-insight and drives product growth with clarity and trust.
Malaysian Reserve
an hour ago
- Malaysian Reserve
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies
The progressive supranuclear palsy market is expected to witness steady growth due to increasing disease awareness, advancements in diagnostic tools, and ongoing clinical research focused on disease-modifying therapies. Rising prevalence of neurodegenerative disorders, coupled with the aging global population, is driving the demand for novel treatments. LAS VEGAS, Aug 7, 2025 /PRNewswire/ — DelveInsight's Progressive Supranuclear Palsy Market Insights report includes a comprehensive understanding of current treatment practices, progressive supranuclear palsy emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Progressive Supranuclear Palsy Market Report According to DelveInsight's analysis, the market size for progressive supranuclear palsy in the 7MM is expected to grow significantly by 2034. The United States accounted for the highest progressive supranuclear palsy treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Approximately one in every 100,000 individuals over the age of 60 is affected by progressive supranuclear palsy. Among all the phenotype-specific cases of PSP, Richardson's syndrome accounted for more than 50% of cases in 2024. Leading progressive supranuclear palsy companies developing emerging therapies, such as Amylyx Pharmaceuticals, AlzProtect, Transposon Therapeutics, Ferrer, Asceneuron, UCB Biopharma, Novartis, and others, are developing new progressive supranuclear palsy treatment drugs that can be available in the progressive supranuclear palsy market in the coming years. The promising progressive supranuclear palsy therapies in the pipeline include AMX0035, AZP2006, TPN-101, FNP-223/ASN90, Bepranemab (UCB0107), NIO752, and others. Discover the progressive supranuclear palsy new treatment @ New Treatments for Progressive Supranuclear Palsy Progressive Supranuclear Palsy Market Dynamics The progressive supranuclear palsy market dynamics are expected to change in the coming years. The progressive supranuclear palsy market is driven by increasing disease awareness, advancements in diagnostic technologies, and growing research efforts to develop disease-modifying therapies. Rising prevalence of neurodegenerative disorders, particularly among the aging population, is further fueling the demand for effective PSP treatment options. Strategic collaborations between pharmaceutical companies and research institutions are accelerating drug discovery and clinical trials, while regulatory incentives such as orphan drug designations are encouraging innovation in this rare disease space. Additionally, the growing adoption of advanced imaging techniques and biomarker-based diagnostics is enabling early and accurate diagnosis, creating a favorable environment for therapeutic interventions and market growth. As potential therapies are being investigated for the treatment of progressive supranuclear palsy, it is safe to predict that the treatment space will significantly impact the progressive supranuclear palsy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the progressive supranuclear palsy market in the 7MM. However, several factors may impede the growth of the progressive supranuclear palsy market. A major challenge is the limited understanding of the disease's underlying pathophysiology, which complicates the identification of viable therapeutic targets. The small patient population and the rarity of PSP restrict the scope of clinical trials, leading to high costs, longer timelines, and recruitment difficulties. Additionally, the absence of disease-modifying treatments and reliance on symptomatic therapies limit market growth, as current treatment options provide only minimal clinical benefit. Regulatory hurdles, stringent approval processes, and a high failure rate in late-stage clinical trials further exacerbate the challenges. Moreover, the lack of robust diagnostic tools and biomarkers often delays early diagnosis, reducing the potential for timely interventions and effective disease management. Progressive Supranuclear Palsy Treatment Market At present, no approved medications or standardized clinical guidelines exist specifically for the treatment of progressive supranuclear palsy. Management focuses on alleviating symptoms, providing supportive care, and enhancing the patient's quality of life. Drugs commonly prescribed for Parkinson's disease, such as levodopa, may offer some relief from motor symptoms like rigidity, tremors, and bradykinesia, but their effectiveness in PSP is generally limited and short-lived. Dopamine agonists, including amantadine and ropinirole, can be used alone or in combination with levodopa, though they provide only modest benefits. Beyond medications, a multidisciplinary care approach is crucial. Physical therapy aids in improving mobility and balance, occupational therapy assists with daily activities, and speech and swallowing therapy helps manage communication and feeding challenges. These supportive strategies play a key role in preserving the best possible quality of life for PSP patients. To know more about progressive supranuclear palsy treatment options, visit @ Approved Progressive Supranuclear Palsy Drugs Progressive Supranuclear Palsy Pipeline Therapies and Key Companies The emerging pipeline for PSP includes AZP2006 (AlzProtect), AMX0035 (Amylyx Pharmaceuticals), TPN-101 (Transposon Therapeutics), FNP-223 (Ferrer), and others. AZP2006 is an orally administered small molecule featuring a unique mechanism of action. It acts through a neurotrophic factor, offering enhanced neuroprotective effects combined with anti-inflammatory activity in the nervous system. This compound shows significant therapeutic promise for addressing the underlying pathological mechanisms of progressive supranuclear palsy (PSP) and other tau-related disorders, including Alzheimer's disease. In September 2024, the company announced the successful completion of a Phase IIa clinical trial of AZP2006 for PSP treatment. Throughout a 3-month Phase IIa study in PSP patients, the drug demonstrated promising clinical and biomarker efficacy signals. These findings were further corroborated by results from a 6-month open-label extension study, strengthening its therapeutic potential. AZP2006 has also been granted Orphan Drug Designation by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In April 2025, the Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF), and Anne-Marie Wills (Massachusetts General Hospital), selected two promising drug candidates, Axon Neuroscience's AADvac1 and Alzprotect's AZP2006, as the first compounds to be tested under the platform trial. This initiative aims to accelerate the development of effective treatments for PSP, a rare and fatal neurodegenerative disorder. AMX0035 is an oral, fixed-dose combination therapy composed of sodium phenylbutyrate and taurursodiol (also known as ursodoxicoltaurine). It has a strong mechanistic rationale for PSP, targeting critical upstream pathways involved in disease pathogenesis, such as the unfolded protein response and mitochondrial dysfunction. Additionally, AMX0035 has been shown to lower p-tau levels in Alzheimer's disease studies. Currently, AMX0035 is being evaluated in a global Phase IIb/III (ORION) clinical trial, which aims to determine its efficacy, safety, and tolerability in PSP patients. The trial is expected to conclude by April 2026, with Amylyx Pharmaceuticals planning to release safety and efficacy data from the unblinded Phase IIb portion of the study in Q3 2025. The anticipated launch of these emerging therapies are poised to transform the progressive supranuclear palsy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the progressive supranuclear palsy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Discover more about progressive supranuclear palsy marketed and pipeline drugs @ Progressive Supranuclear Palsy Clinical Trials Recent Developments in the Progressive Supranuclear Palsy Market In June 2025, Ferrer announced that the US FDA has granted the Fast Track designation to FNP-223 for treatment of patients with progressive supranuclear palsy (PSP). In April 2025, AlzProtect's AZP2006 was chosen as one of the initial two therapies to be tested in the newly launched national Phase II Platform Trial for Progressive Supranuclear Palsy (PSP) in the United States. Funded by the National Institute on Aging (NIH), the trial aims to fast-track the development of effective treatments for PSP. Progressive Supranuclear Palsy Overview Progressive supranuclear palsy is a rare neurodegenerative disorder that affects movement, balance, speech, and eye movements. It is caused by the accumulation of abnormal tau protein in certain areas of the brain, leading to the degeneration of nerve cells. While the exact cause of PSP is not fully understood, it is believed to involve a combination of genetic and environmental factors. PSP typically affects individuals over the age of 60 and progresses gradually over time. The symptoms of PSP include difficulties with balance and frequent falls, stiffness and slow movements similar to Parkinson's disease, and problems with eye movements, particularly the inability to move the eyes up and down. Other symptoms may include speech and swallowing difficulties, personality changes, irritability, depression, and cognitive decline. Unlike Parkinson's disease, tremors are uncommon in PSP, which helps in differentiating the two conditions. Diagnosis of PSP is challenging as there is no specific test to confirm the condition. It is primarily diagnosed based on clinical symptoms, neurological examinations, and the exclusion of other similar conditions. Brain imaging techniques, such as MRI, may reveal characteristic brain changes like midbrain shrinkage, which supports the diagnosis. Early recognition of eye movement abnormalities and postural instability is crucial for an accurate diagnosis. Progressive Supranuclear Palsy Epidemiology Segmentation The progressive supranuclear palsy epidemiology section provides insights into the historical and current progressive supranuclear palsy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The progressive supranuclear palsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Prevalent Cases of PSP Total Diagnosed Prevalent Cases of PSP Gender-specific Diagnosed Prevalent Cases of PSP Phenotype-specific Diagnosed Prevalent Cases of PSP Comorbidity Associated Cases with PSP Progressive Supranuclear Palsy Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan]. Key Progressive Supranuclear Palsy Companies Amylyx Pharmaceuticals, AlzProtect, Transposon Therapeutics, Ferrer, Asceneuron, UCB Biopharma, Novartis, and others Key Progressive Supranuclear Palsy Therapies AMX0035, AZP2006, TPN-101, FNP-223/ASN90, Bepranemab (UCB0107), NIO752, and others Scope of the Progressive Supranuclear Palsy Market Report Therapeutic Assessment: Progressive Supranuclear Palsy current marketed and emerging therapies Progressive Supranuclear Palsy Market Dynamics: Key Market Forecast Assumptions of Emerging Progressive Supranuclear Palsy Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Progressive Supranuclear Palsy Market Access and Reimbursement Download the report to understand which factors are driving progressive supranuclear palsy therapeutics market trends @ Progressive Supranuclear Palsy Market Trends Table of Contents 1. Progressive Supranuclear Palsy Market Key Insights 2. Progressive Supranuclear Palsy Market Report Introduction 3. Progressive Supranuclear Palsy Market Overview at a Glance 4. Progressive Supranuclear Palsy Market Executive Summary 5. Disease Background and Overview 6. Progressive Supranuclear Palsy Treatment and Management 7. Progressive Supranuclear Palsy Epidemiology and Patient Population 8. Patient Journey 9. Progressive Supranuclear Palsy Marketed Drugs 10. Progressive Supranuclear Palsy Emerging Drugs 11. Seven Major Progressive Supranuclear Palsy Market Analysis 12. Progressive Supranuclear Palsy Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis Related Reports Progressive Supranuclear Palsy Pipeline Progressive Supranuclear Palsy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PSP companies, including Amylyx Pharmaceuticals, Transposon Therapeutics, Inc., Ferrer International, Novartis Pharmaceuticals, TauC3 Biologics, among others. Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, among others. Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol-Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC, among others. Dementia Market Dementia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies including Eisai Co., Ltd., Eli Lilly and Company, Novartis AG, DAIICHI SANKYO COMPANY, LIMITED, AbbVie Inc., Lundbeck, Biogen, Cipla, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ + Logo: View original content:
Malaysian Reserve
an hour ago
- Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of American Woodmark Corporation (NASDAQ: AMWD)
NEW YORK, Aug. 7, 2025 /PRNewswire/ — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the 'M&A Class Action Firm'), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating American Woodmark Corporation (NASDAQ: AMWD) related to its sale to MasterBrand, Inc. Under the terms of the proposed transaction, each share of American common stock will be exchanged for 5.150 shares of MasterBrand common stock. Is it a fair deal? Click here for more info It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@ or by telephone at (212) 971-1341. Contact:Juan Monteverde, & ASSOCIATES PCThe Empire State Building350 Fifth Ave. Suite 4740New York, NY 10118United States of Americajmonteverde@ (212) 971-1341 Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( Prior results do not guarantee a similar outcome with respect to any future matter.
